Another phase II trial investigated the role of ZV0203, a novel pertuzumab-based antibody–drug conjugate (ADC), in patients with HER2 positive advanced solid tumours, including GC, with positive preliminary results [25]. This evidence concerns the gene ERBB2 and gastric cancer.